Why Terra Nitrogen, Textura, and Aerie Pharmaceuticals Soared Today

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

Those looking only at end-of-day headlines will focus on the fact that the Dow and S&P 500 posted losses for the fourth consecutive day, as relatively strong economic data made some investors nervous about the potential for the Federal Reserve to pull back on its stimulus measures earlier rather than later. But what the closing numbers omit is that stocks were down much more dramatically earlier in the day before news came out that the economy held up relatively well during the October government shutdown. That helped cut losses, and Terra Nitrogen (NYSE: TNH  ) , Textura (NYSE: TXTR  ) , and Aerie Pharmaceuticals (NASDAQ: AERI  ) all climbed sharply on the day.

Terra Nitrogen climbed 9% in sympathy with CF Industries (NYSE: CF  ) , which owns the master limited partnership's general partner. CF gained more than 10% on news that it's looking at dropping more of its assets into an MLP, helping it take even further advantage of favorable tax laws governing the pass-through business entities. Cheap natural gas has allowed CF and Terra Nitrogen to look at potential expansion, and CF's decision to sell off its phosphate business to Mosaic gives it more latitude to use capital in shareholder-friendly ways. Yet CF's optimism also speaks to Terra Nitrogen's potential to deliver strong growth for years to come.

Textura gained 11% as the cloud-based construction-industry software maker finalized its acquisition of LATISTA, which helps construction-project participants collaborate on project-related tasks. By adding mobile solutions to its arsenal, Textura hopes to become the go-to solution for construction companies seeking to manage their projects more efficiently. With LATISTA having announced a new iPad-based building-information-model sharing program today, Textura investors got their first look at how the acquisition could pay off in the long run.

Aerie Pharmaceuticals jumped 13% as an analyst firm made positive comments on the stock in advance of its third-quarter results. After the bell, the developmental-stage pharma company reported a net loss of $10.9 million for the quarter. Yet with several potential glaucoma drugs in its pipeline, including its most advanced AR-13324 dual-action once-daily drug, Aerie is well positioned to begin phase 3 trials in the middle of next year in hopes of submitting an application for FDA approval by 2016.

Get the growth you deserve
Have your stocks posted gains like these stocks did today? Motley Fool co-founder David Gardner, founder of the world's No. 1 growth-stock newsletter, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth-stock superstars, with you! It's a special 100% free report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains, and click here for instant access to a whole new game plan of stock picks to help power your portfolio.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2752926, ~/Articles/ArticleHandler.aspx, 4/17/2014 3:05:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

TREND TRACKER: Get Rich When the Web Goes Dark

It's time to say "goodbye" to your Internet! One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Big money is already on the move. Don't be too late to the party – find out the 1 stock to own when the Web goes dark.